Coronavirus (COVID 19) Vaccine Pipeline Assessment 2020

April 2020 | 135 pages | ID: C6B5DADBB9D1EN
DPI Research

Abstracts

“Coronavirus (COVID 19) Vaccine Pipeline Assessment 2020” provides a comprehensive analysis of the fast-evolving, high-growth global Coronavirus (COVID 19) vaccine market. The report offers the most up-to-date industry data on the actual market situation for the Coronavirus (COVID 19) vaccine.

The report explores a detailed analysis of the introduction of the coronavirus, pathogen characteristics, signs and symptoms, transmission, and prevention. It also evaluates the vaccines developed against MERS-CoV and SARS-CoV. The report reviews a clear insight into the funding of the Coronavirus (COVID-19) vaccine research. The report also offers comprehensive information about the recruiting clinical trials statement by phase, trial status, study sponsor name, and study phase. The report investigates detailed insights about countries, territories, or areas with reported laboratory-confirmed Coronavirus (COVID-19) cases and deaths. Key trends in terms of collaboration and partnership deals are analyzed with details.

The report concludes with the profiles of the key vaccine developers in the global coronavirus vaccine market. The key players are evaluated on the various parameters such as business overview, promising vaccine in clinical development, and recent development.

Report Scope:

• Extensive coverage of the Coronavirus (COVID-19) vaccine under development
• Detailed Insights of the Introduction, Pathogen Characteristics, Signs and Symptoms, Transmission and Prevention
• Provides Comprehensive Insights on the Funding of the Coronavirus (COVID-19) Vaccine Research
• Thoroughly Evaluates Vaccines Developed Against MERS-CoV and SARS-CoV
• Reviews Most Recent Clinical Trials of the Coronavirus Vaccines
• Scrutinizes Countries, Territories or Areas with Reported Laboratory-Confirmed Coronavirus (COVID-19) Cases and Deaths
• Provides Key Trends with Respect to Collaboration and Partnership Deals
• An Insightful Analysis of the Key Vaccine Developers Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

Key Vaccine Developers Covered in the Report

• University of Oxford
• Clover Biopharmaceuticals/Dynavax/GlaxoSmithKline
• Heat Biologics Inc./University of Miami
• Inovio Pharmaceuticals Inc
• Janssen Pharmaceutical
• Sanofi Pasteur/GlaxoSmithKline (GSK)
• Moderna/NIAID
• Novavax
• Sanofi Pasteur/Translate Bio Inc.
• Vaxart Inc.
• Altimmune
• Medicago
• BioNTech/Pfizer/Fosun Pharma
• GeoVax/BravoVax
• Arcturus Therapeutics/Duke-NUS
• CanSino Biological Inc/Beijing Institute of Biotechnology
• Takis Biotech/Applied DNA Sciences/Evvivax
• Cobra Biologics/Karolinska Institute
• Zydus Cadila
• Codagenix/Serum Institute of India
• Greffex
• ExpreS2ion Biotechnologies ApS
• Vaxil Bio Therapeutics
• Flow Pharma Inc
• AJ Vaccines
• Generex Biotechnology/EpiVax
• Immunomic Therapeutics/EpiVax/PharmaJet
• iBio Inc/CC-Pharming Ltd/Infectious Disease Research Institute
• VIDO-InterVac/University of Saskatchewan/International Vaccine Institute
• Tonix Pharmaceuticals/Southern Research
• IAVI/Batavia Biosciences
• Curevac
• Imophoron Ltd/University of Bristol
• BioNet Asia
• Sinovac/Dynavax
• BIOCAD
• University of Pittsburgh

Contents

1. EXECUTIVE SUMMARY

2. CORONAVIRUS (COVID-19) - INTRODUCTION, PATHOGEN CHARACTERISTICS, SIGNS AND SYMPTOMS, TRANSMISSION AND PREVENTION

2.1 Introduction
2.2 Pathogen Characteristics
2.3 Signs and Symptoms
2.4 Transmission
2.5 Prevention

3. FUNDING IN THE CORONAVIRUS (COVID-19) VACCINE RESEARCH

4. VACCINES DEVELOPED AGAINST MERS-COV

5. VACCINES DEVELOPED AGAINST SARS-COV

6. CORONAVIRUS (COVID-19) VACCINE CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY AND COUNTRY

7. COUNTRIES, TERRITORIES OR AREAS WITH REPORTED LABORATORY-CONFIRMED CORONAVIRUS (COVID-19) CASES AND DEATHS

8. MAJOR PARTNERSHIP AND COLLABORATION DEALS IN THE CORONAVIRUS (COVID – 19) VACCINE MARKET

8.1 Collaboration Deals
8.2 Partnership Deals

9. KEY VACCINE DEVELOPERS ANALYSIS

9.1 University of Oxford
  9.1.1 Business Overview
  9.1.2 Promising Coronavirus Vaccines in the Clinical Development
  9.1.3 Recent Development
9.2 Clover Biopharmaceuticals/Dynavax/GlaxoSmithKline
  9.2.1 Business Overview
  9.2.2 Promising Coronavirus Vaccines in the Clinical Development
  9.2.3 Recent Development
9.3 Heat Biologics Inc./University of Miami
  9.3.1 Business Overview
  9.3.2 Promising Coronavirus Vaccines in the Clinical Development
  9.3.3 Recent Development
9.4 Inovio Pharmaceuticals Inc
  9.4.1 Business Overview
  9.4.2 Promising Coronavirus Vaccines in the Clinical Development
  9.4.3 Recent Development
9.5 Janssen Pharmaceutical
  9.5.1 Business Overview
  9.5.2 Promising Coronavirus Vaccines in the Clinical Development
  9.5.3 Recent Development
9.6 Sanofi Pasteur/GlaxoSmithKline (GSK)
  9.6.1 Business Overview
  9.6.2 Promising Coronavirus Vaccines in the Clinical Development
  9.6.3 Recent Development
9.7 Moderna/NIAID
  9.7.1 Business Overview
  9.7.2 Promising Coronavirus Vaccines in the Clinical Development
  9.7.3 Recent Development
9.8 Novavax
  9.8.1 Business Overview
  9.8.2 Promising Coronavirus Vaccines in the Clinical Development
  9.8.3 Recent Development
9.9 Sanofi Pasteur/Translate Bio Inc.
  9.9.1 Business Overview
  9.9.2 Promising Coronavirus Vaccines in the Clinical Development
  9.9.3 Recent Development
9.10 Vaxart Inc.
  9.10.1 Business Overview
  9.10.2 Promising Coronavirus Vaccines in the Clinical Development
  9.10.3 Recent Development
9.11 Altimmune
  9.11.1 Business Overview
  9.11.2 Promising Coronavirus Vaccines in the Clinical Development
  9.11.3 Recent Development
9.12 Medicago
  9.12.1 Business Overview
  9.12.2 Promising Coronavirus Vaccines in the Clinical Development
  9.12.3 Recent Development
9.13 BioNTech/Pfizer/Fosun Pharma
  9.13.1 Business Overview
  9.13.2 Promising Coronavirus Vaccines in the Clinical Development
  9.13.3 Recent Development
9.14 GeoVax/BravoVax
  9.14.1 Business Overview
  9.14.2 Promising Coronavirus Vaccines in the Clinical Development
  9.14.3 Recent Development
9.15 Arcturus Therapeutics/Duke-NUS
  9.15.1 Business Overview
  9.15.2 Promising Coronavirus Vaccines in the Clinical Development
  9.15.3 Recent Development
9.16 CanSino Biological Inc/Beijing Institute of Biotechnology
  9.16.1 Business Overview
  9.16.2 Promising Coronavirus Vaccines in the Clinical Development
  9.16.3 Recent Development
9.17 Takis Biotech/Applied DNA Sciences/Evvivax
  9.17.1 Business Overview
  9.17.2 Promising Coronavirus Vaccines in the Clinical Development
  9.17.3 Recent Development
9.18 Cobra Biologics/Karolinska Institute
  9.18.1 Business Overview
  9.18.2 Promising Coronavirus Vaccines in the Clinical Development
  9.18.3 Recent Development
9.19 Zydus Cadila
  9.19.1 Business Overview
  9.19.2 Promising Coronavirus Vaccines in the Clinical Development
  9.19.3 Recent Development
9.20 Codagenix/Serum Institute of India
  9.20.1 Business Overview
  9.20.2 Promising Coronavirus Vaccines in the Clinical Development
  9.20.3 Recent Development
9.21 Greffex
  9.21.1 Business Overview
  9.21.2 Promising Coronavirus Vaccines in the Clinical Development
  9.21.3 Recent Development
9.22 ExpreS2ion Biotechnologies ApS
  9.22.1 Business Overview
  9.22.2 Promising Coronavirus Vaccines in the Clinical Development
  9.22.3 Recent Development
9.23 Vaxil Bio Therapeutics
  9.23.1 Business Overview
  9.23.2 Promising Coronavirus Vaccines in the Clinical Development
  9.23.3 Recent Development
9.24 Flow Pharma Inc
  9.24.1 Business Overview
  9.24.2 Promising Coronavirus Vaccines in the Clinical Development
  9.24.3 Recent Development
9.25 AJ Vaccines
  9.25.1 Business Overview
  9.25.2 Promising Coronavirus Vaccines in the Clinical Development
  9.25.3 Recent Development
9.26 Generex Biotechnology/EpiVax
  9.26.1 Business Overview
  9.26.2 Promising Coronavirus Vaccines in the Clinical Development
  9.26.3 Recent Development
9.27 Immunomic Therapeutics/EpiVax/PharmaJet
  9.27.1 Business Overview
  9.27.2 Promising Coronavirus Vaccines in the Clinical Development
  9.27.3 Recent Development
9.28 iBio Inc/CC-Pharming Ltd/Infectious Disease Research Institute
  9.28.1 Business Overview
  9.28.2 Promising Coronavirus Vaccines in the Clinical Development
  9.28.3 Recent Development
9.29 VIDO-InterVac/University of Saskatchewan/International Vaccine Institute
  9.29.1 Business Overview
  9.29.2 Promising Coronavirus Vaccines in the Clinical Development
  9.29.3 Recent Development
9.30 Tonix Pharmaceuticals/Southern Research
  9.30.1 Business Overview
  9.30.2 Promising Coronavirus Vaccines in the Clinical Development
  9.30.3 Recent Development
9.31 IAVI/Batavia Biosciences
  9.31.1 Business Overview
  9.31.2 Promising Coronavirus Vaccines in the Clinical Development
  9.31.3 Recent Development
9.32 Curevac
  9.32.1 Business Overview
  9.32.2 Promising Coronavirus Vaccines in the Clinical Development
  9.32.3 Recent Development
9.33 Imophoron Ltd/University of Bristol
  9.33.1 Business Overview
  9.33.2 Promising Coronavirus Vaccines in the Clinical Development
  9.33.3 Recent Development
9.34 BioNet Asia
  9.34.1 Business Overview
  9.34.2 Promising Coronavirus Vaccines in the Clinical Development
  9.34.3 Recent Development
9.35 Sinovac/Dynavax
  9.35.1 Business Overview
  9.35.2 Promising Coronavirus Vaccines in the Clinical Development
  9.35.3 Recent Development
9.36 BIOCAD
  9.36.1 Business Overview
  9.36.2 Promising Coronavirus Vaccines in the Clinical Development
  9.36.3 Recent Development
9.37 University of Pittsburgh
  9.37.1 Business Overview
  9.37.2 Promising Coronavirus Vaccines in the Clinical Development
  9.37.3 Recent Development

List Of Tables

LIST OF TABLES:

Table 4–1: Vaccines Developed Against MERS-CoV
Table 5–1: Vaccines Developed Against SARS-CoV
Table 7–1: Countries, Territories or Areas with Reported Laboratory-Confirmed Coronavirus (COVID-19) Cases and Deaths
Table 9–1: University of Oxford Promising Coronavirus Vaccines in the Clinical Development
Table 9–2: Clover Biopharmaceuticals/Dynavax/GSK Promising Coronavirus Vaccines in the Clinical Development
Table 9–3: Heat Biologics Inc/University of Miami Promising Coronavirus Vaccines in the Clinical Development
Table 9–4: Inovio Pharmaceuticals Inc Promising Coronavirus Vaccines in the Clinical Development
Table 9–5: Janssen Pharmaceutical Promising Coronavirus Vaccines in the Clinical Development
Table 9–6: Sanofi Pasteur/GlaxoSmithKline (GSK) Promising Coronavirus Vaccines in the Clinical Development
Table 9–7: Moderna/NIAID Promising Coronavirus Vaccines in the Clinical Development
Table 9–8: Novavax Promising Coronavirus Vaccines in the Clinical Development
Table 9–9: Sanofi/Translate Bio Promising Coronavirus Vaccines in the Clinical Development
Table 9–10: Vaxart Inc. Promising Vaccines in the Clinical Development
Table 9–11: Altimmune Promising Coronavirus Vaccines in the Clinical Development
Table 9–12: Medicago Promising Coronavirus Vaccines in the Clinical Development
Table 9–13: BioNTech/Pfizer/Fosun Pharma Promising Coronavirus Vaccines in the Clinical Development
Table 9–14: GeoVax/BravoVax Promising Coronavirus Vaccines in the Clinical Development
Table 9–15: Arcturus Therapeutics/Duke-NUS Promising Coronavirus Vaccines in the Clinical Development
Table 9–16: CanSino Biological Inc/ Beijing Institute of Biotechnology Promising Coronavirus Vaccines in the Clinical Development
Table 9–17: Takis/Applied DNA Sciences/Evvivax Promising Coronavirus Vaccines in the Clinical Development
Table 9–18: Cobra Biologics/ Karolinska Institute Promising Coronavirus Vaccines in the Clinical Development
Table 9–19: Zydus Cadila Promising Coronavirus Vaccines in the Clinical Development
Table 9–20: Codagenix/Serum Institute of India Promising Coronavirus Vaccines in the Clinical Development
Table 9–21: Greffex Promising Coronavirus Vaccines in the Clinical Development
Table 9–22: ExpreS2ion Biotechnologies ApS Promising Coronavirus Vaccines in the Clinical Development
Table 9–23: Vaxil Bio Therapeutics Promising Coronavirus Vaccines in the Clinical Development
Table 9–24: Flow Pharma Inc Promising Coronavirus Vaccines in the Clinical Development
Table 9–25: AJ Vaccines Promising Coronavirus Vaccines in the Clinical Development
Table 9–26: Generex Biotechnology/EpiVax Promising Coronavirus Vaccines in the Clinical Development
Table 9–27: Immunomic Therapeutics, EpiVax & PharmaJet Promising Coronavirus Vaccines in the Clinical Development
Table 9–28: iBio/CC-Pharming/IDRI Promising Coronavirus Vaccines in the Clinical Development
Table 9–29: VIDO-InterVac/University of Saskatchewan/IVI Promising Coronavirus Vaccines in the Clinical Development
Table 9–30: Tonix Pharmaceuticals/Southern Research Promising Coronavirus Vaccines in the Clinical Development
Table 9–31: IAVI/Batavia Biosciences Promising Coronavirus Vaccines in the Clinical Development
Table 9–32: Curevac Promising Coronavirus Vaccines in the Clinical Development
Table 9–33: Imophoron Ltd/University of Bristol Promising Coronavirus Vaccines in the Clinical Development
Table 9–34: BioNet Asia Promising Coronavirus Vaccines in the Clinical Development
Table 9–35: Sinovac/Dynavax Promising Coronavirus Vaccines in the Clinical Development
Table 9–36: BIOCAD Promising Coronavirus Vaccines in the Clinical Development
Table 9–37: University of Pittsburgh Promising Coronavirus Vaccines in the Clinical Development